Vertex reports FY2025 revenue $12.0B (+9% YoY); guides FY2026 revenue $12.95-13.1B

VERTEX PHARMACEUTICALS INC / MA

2025-FY EPS reported $15.32 vs consensus $5.17 ▲ beat (+196.1%)

FY2025 total revenue $12.0B, up 9% YoY; Q4 revenue $3.19B, up 10% YoY.
GAAP net income $4.0B in FY2025 vs net loss of $(536)M in 2024; cash $12.3B.
FY2026 revenue guidance $12.95–$13.1B; non-CF product revenue expected ≥$500M.
JOURNAVX: >550,000 prescriptions filled in 2025; coverage for >200M U.S. lives.
Rolling BLA for povetacicept in IgAN on track for completion in H1 2026; ALYFTREK pediatric study completed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.